Mytricon 150 mg/ml Suspension for injection.
PDF Leaflet Revision Date: 04 December 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Endometriosis, contraception, endometrial and renal cancer.
Dosage (summary)
50 mg weekly or 100 mg every 2 weeks for endometriosis; 150 mg every 3 months for contraception; 400-1000 mg weekly for cancer.
Special Populations
- Hepatic impairment
- Renal impairment
- Adolescents (post-menarche)
Pregnancy & Breastfeeding
Contraindicated in pregnancy; use with caution in breastfeeding after 6 weeks postpartum.
Key Drug Interactions
- Aminoglutethimide may decrease bioavailability
- Oral anticoagulants
Contraindications
- Hypersensitivity to medroxyprogesterone acetate
- Undiagnosed vaginal bleeding
- Severe liver impairment
- Thrombophlebitis
- Known or suspected pregnancy
Common side effects
- Weight gain
- Headache
- Nervousness
- Abdominal pain
- Dizziness
Counselling Points
- Monitor for mood changes
- Discuss contraceptive options
- Counsel on delayed return to fertility
Serious warnings
- Loss of bone mineral density
- Risk of depression
- Thromboembolic disorders
Important Disclaimer
The Mytricon 150 mg/ml Suspension for injection. professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
